Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 31, 2026
Direxion Daily FTSE China Bull 3X Shares (YINN) Climbs +46% in 30 Days on Policy Support

Direxion Daily FTSE China Bull 3X Shares (YINN) Climbs +46% in 30 Days on Policy Support

Key Takeaways

  • YINN surged approximately 46% over the last 30 days, reflecting a sharp V-shaped recovery in Chinese equities after a steep mid-year selloff.
  • The rally was driven by coordinated state-backed intervention, with sovereign wealth funds deploying over 600 billion yuan into Chinese stocks and ETFs.
  • The fund's 3x daily leveraged structure amplified the underlying FTSE China 50 Index's recovery, contributing to outsized returns relative to unleveraged China equity benchmarks.
  • Over the broader quarter, YINN remained down approximately 7% despite the recent surge, underscoring the extreme volatility embedded in leveraged China exposure.
  • Policy catalysts — including Politburo stimulus signals, CSRC investor symposiums, and widespread corporate buybacks — have been the primary engines of the rebound.

Direxion Daily FTSE China Bull 3X Shares (YINN) Overview and Portfolio Exposure

YINN is a leveraged exchange-traded fund that seeks daily investment results, before fees and expenses, corresponding to 300% of the daily performance of the FTSE China 50 Index. The index tracks the 50 largest and most liquid Chinese companies listed on the Hong Kong Stock Exchange, spanning sectors such as financials, technology, consumer discretionary, and energy. The fund is issued by Direxion and carries a net expense ratio of 1.34%.

Rather than holding the underlying index constituents directly, YINN primarily achieves its leveraged exposure through swap agreements and a sizable allocation to the iShares China Large-Cap ETF (FXI), which comprised approximately 62% of reported holdings. The remainder consists of cash instruments and additional swap positions used to achieve the 3x multiplier. This structure means YINN does not directly own shares of companies such as Tencent, Alibaba, or Meituan; instead, its returns are driven by derivative contracts referencing the performance of those names. The concentrated nature of the portfolio means the fund's daily price action closely mirrors amplified moves in Chinese large-cap equities.

Direxion Daily FTSE China Bull 3X Shares (YINN) Price Performance: Last 30 Days vs. Quarter

During the last 30 days, YINN rose approximately 46%, climbing from $22.27 at the start of July to $32.47 by month-end. The move was not linear; the fund experienced several sharp upswings punctuated by single-day pullbacks, characteristic of leveraged products responding to a fast-moving policy-driven recovery in Chinese markets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Zooming out to the full quarter, the picture is more sobering. From late April, when YINN traded near $34.82, the fund declined approximately 7% through late July — a period that included a dramatic drawdown to as low as $21.72 in late June. This path illustrates the immense intra-quarter volatility that leveraged China ETFs can exhibit.

What Drove YINN Price in the Last 30 Days

The 30-day rally in YINN was overwhelmingly policy-driven. In mid-July, Chinese regulators and state-backed entities launched a coordinated stabilization campaign after sharp equity market declines triggered by global tech weakness and geopolitical concerns. Two major state-owned capital platforms — China Chengtong Holdings and China Reform Holdings — jointly announced over 600 billion yuan in stock and ETF purchases, directly targeting broad-market and technology-focused funds.

The China Securities Regulatory Commission reinforced the message by holding a widely publicized investor symposium, pledging to maintain stable market operations and protect investor interests. This was followed by a flurry of corporate buyback announcements, with over 40 listed companies disclosing repurchase plans within days. Five major Chinese insurers — including China Life, PICC, and Ping An — simultaneously declared their commitment to being long-term patient capital in domestic equities.

International sentiment pivoted as well. Citi upgraded Chinese equities to overweight, and Goldman Sachs published research recommending a rotation from South Korean AI stocks into Chinese AI value-chain names. The Politburo's late-July readout, signaling readiness to deploy new stimulus measures, provided an additional catalyst. Technology shares led the charge: the STAR 50 Index surged 10.73% in a single session on July 21, while the ChiNext Index gained 7.05%.

What Drove YINN Performance Over the Last Quarter

Over the full quarter, YINN's approximately 7% decline reflects a tale of two markets. From late April through late June, Chinese equities came under severe pressure as a global selloff in technology and artificial intelligence-related names spilled over into Hong Kong-listed Chinese tech stocks. Concerns around U.S.-China trade tensions, a strengthening U.S. dollar, and weaker-than-expected second-quarter Chinese GDP growth of 4.3% year-over-year further weighed on sentiment.

The FTSE China 50 Index, which YINN tracks at 3x leverage, fell sharply during this window, and the leveraged structure compounded the downside. YINN dropped from around $38.86 in mid-May to $21.72 by June 25, a decline exceeding 44% in roughly six weeks. Institutional flows reflected the uncertainty, with record-breaking inflows exceeding 150 billion yuan in a single week once state-backed buying commenced in mid-July.

YINN ETF Outlook: What Investors Should Watch Next

The trajectory of YINN over the coming months will depend heavily on whether Chinese policymakers follow through with the stimulus measures hinted at in recent Politburo communications. Key data releases — including the upcoming official manufacturing PMI for July — will be critical in shaping the policy response. Externally, U.S. interest rate expectations and dollar strength remain important variables, as a persistently strong dollar has historically pressured emerging-market equities.

Investors should also remain mindful of the structural characteristics of leveraged ETFs. YINN is designed for daily holding periods and resets its leverage exposure each trading day. Over extended holding periods, compounding and volatility decay can cause returns to deviate meaningfully from a simple 3x multiple of the index's cumulative performance. The fund's concentrated exposure to Hong Kong-listed Chinese large caps means elevated volatility is likely to persist.

AI Screener

In my own research process, Tickeron's AI Screener has become a useful complement when I want to scan beyond a single fund like YINN. It applies AI-driven technical indicators, fundamental metrics, and pattern recognition across thousands of securities, helping surface ideas that match specific criteria without manual effort. I find it efficient for identifying broader trends alongside focused ETF analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: YINN

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


YINN in upward trend: price rose above 50-day moving average on July 27, 2026

YINN moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend. In of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for YINN crossed bullishly above the 50-day moving average on July 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where YINN advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 162 cases where YINN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for YINN moved out of overbought territory on August 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 68 cases where YINN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on August 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on YINN as a result. In of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where YINN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

YINN broke above its upper Bollinger Band on July 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Industry description

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the FTSE China 50 Index. The fund, under normal circumstances, invests at least 80% of its net assets (plus borrowing for investment purposes) in financial instruments, such as swap agreements, securities of the index, and exchange-traded funds ("ETFs") that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index consists of the 50 largest and most liquid public Chinese companies currently trading on the Hong Kong Stock Exchange. The fund is non-diversified.
View a ticker or compare two or three
YINN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Leveraged Equity
Address
Direxion Shares ETF Trust33 Whitehall Street,10th FloorNew York
Phone
866-476-7523
Web
http://www.direxioninvestments.com/
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.